The UK’s new International Recognition Procedure is intended to “enhance the attractiveness of the UK” by creating an environment where the pharmaceutical sector is able to develop and launch new medicines more quickly for the benefit of public health, according to Julian Beach of the Medicines and Healthcare products Regulatory Agency (MHRA).
At the beginning of 2024, the IRP will replace the European Commission Decision Reliance Procedure (ECDRP), which allows the MHRA to rely on EU approval decisions when considering applications for GB
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?